Apply Same Approval Standards to Psychedelic Drugs

Share

A Kleinfeld Kaplan Becker client has petitioned FDA to “assure that psychedelic drug products are uniformly subject to the same rigorous medical and scientific approval framework applicable to other classes of drugs.” The petition notes that FDA has approved three Commissioner’s National Priority Vouchers for companies studying psychedelic therapies and has finalized a guidance on the design of clinical trials for such drugs.

“Petitioner applauds the efforts to facilitate development of psychedelic drug therapies and looks forward to FDA action on these pending applications,” the petition says, “but seeks to ensure enthusiasm about these new medications does not lead to approvals based on thin data packages or inconsistently applied standards. In accordance with FDA’s mandate of protecting and promoting public health, this citizen petition requests that FDA apply uniform, established statutory approval standards to review and action on these pending NDAs, and future NDAs seeking approval of psychedelic drug products.”

The unidentified petitioner specifically asks that FDA:

  • apply established standards for demonstration of safety and effectiveness set out in the Federal Food, Drug, and Cosmetic Act (FFDCA) and FDA’s implementing regulations to all NDAs seeking approval of psychedelic drug products; and
  • apply those established standards for demonstration of safety and effectiveness in a consistent fashion across all NDAs for psychedelic drug products, subjecting similarly situated applications to the same evidentiary expectations, requests, and standards.

The petition concludes that psychedelic drugs represent a promising new therapeutic class that may provide needed options for patients suffering from chronic, debilitating illnesses. But it says that promise should not be used to justify circumventing statutory approval standards applicable to other drug classes or creating alternative, less regulated pathways for psychedelic access.

“Patients deserve, and the FFDCA requires, that FDA approve only those applications supported by adequate safety and effectiveness data, consistent with the FFDCA and FDA’s implementing regulations,” it says. “Only through adherence to those established standards can the agency assure that patients are not exposed to risks that have not been adequately characterized, and do not forgo or delay treatments with proven benefits in favor of one whose effectiveness is uncertain.”

Read more